Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:activities |
MEK inhibitor
|
| gptkbp:appointed_by |
oral medication
|
| gptkbp:approves |
gptkb:2020
gptkb:FDA |
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
Phase III
NC T01362803 NC T02096268 NC T02335918 NC T02989857 treatment of inoperable plexiform neurofibromas |
| gptkbp:contraindication |
hypersensitivity to the drug
severe liver impairment |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:effective_date |
FDA approved
EMA approved |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Selumetinib
|
| gptkbp:indication |
gptkb:neurofibromatosis_type_1
|
| gptkbp:ingredients |
C16 H14 F3 N3 O3 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L01 X E30
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:lifespan |
approximately 8 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
the brand name Koselugo
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
absorbed in gastrointestinal tract
inhibits ME K1 and ME K2 |
| gptkbp:population |
pediatric patients
adult patients |
| gptkbp:project |
clinical development
|
| gptkbp:research |
ongoing studies for other cancers
studies on dosing regimens investigating combination therapies studies on long-term effects studies on efficacy in adults studies on efficacy in children |
| gptkbp:research_areas |
oncology
rare diseases |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash elevated liver enzymes |
| gptkbp:targets |
ME K1
ME K2 |
| gptkbp:treatment |
with other cancer drugs
|
| gptkbp:type_of |
606143-52-6
|